Table 1 Characteristics of the included studies
Study name (author, year) | Research Type | Country/Continent | Samples | Study design | Multi/single-center | Sequencing platform | Patients were severely ill or immunocompromised | Sample pattern | Pathogen type | TP | FP | FN | TN |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
(Leon, 2018) [24] | Cohort | Spain/Europe | 20 | Retrospective | Single | Illumina | No | Frozen | isolated | 10 | 0 | 10 | 0 |
(Saha, 2019) [28] | Case–control | Bangladesh/Asia | 91 | Retrospective | Single | Illumina | No | Fresh | mixed | 35 | 0 | 11 | 45 |
(Zhang, 2019) [4] | Case–control | China/Asia | 135 | Retrospective | Single | BGISEQ | No | Fresh | isolated | 32 | 6 | 11 | 86 |
(Haston, 2020) [23] | Cohort | USA/America | 20 | Prospective | Single | Illumina | No | Fresh | mixed | 3 | 3 | 0 | 14 |
(Leon, 2020) [25] | Cohort | Spain/Europe | 20 | Retrospective | Single | Illumina | No | Fresh | isolated | 8 | 0 | 12 | 0 |
(Ge, 2021) [22] | Cohort | China/Asia | 101 | Prospective | Single | Illumina | No | Fresh | mixed | 5 | 15 | 0 | 81 |
(Guo, 2021) [29] | Case–control | China/Asia | 17 | Retrospective | Single | BGISEQ | No | Fresh | isolated | 11 | 0 | 4 | 2 |
(Ramchandar, 2021) [21] | Cohort | USA/America | 70 | Prospective | Multi | Illumina | No | Frozen | mixed | 20 | 4 | 5 | 41 |
(Chen, 2022) [30] | Cohort | China/Asia | 127 | Prospective | Single | Illumina | No | Frozen | isolated | 32 | 23 | 27 | 45 |
(Qu, 2022) [26] | Cohort | China/Asia | 15 | Retrospective | Single | BGISEQ | Yes | Frozen | mixed | 10 | 1 | 1 | 3 |